Monroeville company's device approved to assist fertilization
By Alex Nixon
Published: Wednesday, April 17, 2013, 12:01 a.m.
A Monroeville medical device firm says it has an answer for the increasing problem of infertility among couples.
Rinovum Women's Health has started selling a device approved by the Food and Drug Administration called the Stork, which can help improve the chances a woman will get pregnant.
“This is the first step in assisted fertilization,” Rinovum CEO Steve Bollinger said. “Let the Stork be the first step.”
And if Bollinger's plans work out, the device could be as common on drugstore shelves as pregnancy tests and ovulation kits, delivering substantial sales for the 3-year-old company.
The Stork is only available with a prescription, but Bollinger said he's working with the FDA to make it available over the counter.
The $80 at-home device replicates intracervical insemination, a form of artificial insemination traditionally performed in a medical setting, in which semen is deposited at the cervix. Intracervical insemination can increase the likelihood of pregnancy by 10 to 20 percent, Bollinger said.
And it's less invasive and not as expensive as more popular methods of artificial insemination, such as in vitro fertilization ($20,000 to $25,000) and intrauterine insemination ($1,000 to $5,000), he said.
In vitro fertilization involves fertilizing an egg outside the woman's body and then implanting the egg in the uterus. Intrauterine insemination injects a concentrated batch of sperm directly into the uterus.
“We're not the perfect solution for everyone, but we're a darn good solution for a lot of them,” he said.
The 48-year-old Bollinger, a graduate of Franklin Regional High School and the Military Academy at West Point, returned to Pittsburgh several years ago after founding and then selling three health care companies on the East Coast. He joined the Pittsburgh Life Sciences Greenhouse, a South Side incubator for startup companies in the health care industry, and began working on his idea for the Stork.
In January, Rinovum, which changed its name last year from Intimate Bridge 2 Conception Inc., moved out of the Greenhouse and into offices in Monroeville.
“We are proud that Rinovum Women's Health has outgrown the incubator and continues to add employees as they prepare to launch their first product to market,” said John Manzetti, Greenhouse CEO.
The 11-year-old incubator houses five companies and has helped more than 30 companies with startup space over its history.
Rinovum has seven employees and Bollinger said he expects to add three workers by next month. The device is being made by Seko, a contract manufacturer in Warrendale.
Bollinger declined to provide a sales forecast for the company. But he said 1.8 million ovulation kits were sold last year just in CVS and Walgreen drug stores, indicating the number of potential customers who could be interested in the device should it receive clearance for over-the-counter sales.
Alex Nixon is a staff writer for Trib Total Media. He can be reached at 412-320-7928. or firstname.lastname@example.org.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Madoff cut dead client’s payout by creating fake loss, jury told
- Firms transmit market data at near light speed
- Crown Castle to grow
- Range looks to sell Texas drilling assets
- European officials fine first U.S. banks in rate rigging scandal
- Many tellers just scraping by
- Generic drugmaker Mylan completes $1.75B acquisition in India
- Fed says economy ‘trudging’ on
- Stocks struggle as investors weigh economic news
- Reporter want ad: Did your health insurer cancel your plan?
- CMU’s Alice software adds Garfield characters